🇺🇸 FDA
Pipeline program

ENMD-2076

2076-CL-002

Phase 1 small_molecule completed

Quick answer

ENMD-2076 for Multiple Myeloma is a Phase 1 program (small_molecule) at CASI Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
CASI Pharmaceuticals
Indication
Multiple Myeloma
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials